Tetrous
Tetrous, Inc. is a regenerative medicine company developing and commercializing the EnFix family of 100% demineralized bone fiber allograft implants for orthopedic and sports medicine surgeons performing bone-to-tendon repair procedures, including rotator cuff and ACL reconstruction, in the United States, Australia, and New Zealand.
- Company typePrivate
- Founded2019
- HeadquartersSherman Oaks, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tetrous does
Tetrous, Inc. is a privately held regenerative medicine company founded in 2019 as a spin-out of spine allograft company TheraCell, Inc. (later sold to ISTO Biologics in 2022), headquartered in Sherman Oaks, Los Angeles. The company develops and commercializes the EnFix family of 100% demineralized bone fiber (DBF) allograft implants designed to address Enthesis Failure Syndrome by promoting reformation of the native bone-tendon interface (enthesis) rather than the fibrotic scar tissue typically produced by conventional repair. Its core products include EnFix RC for rotator cuff repair with suture anchors, EnFix TAC-T and EnFix TAC-O for anchor-independent or all-suture anchor rotator cuff repair, and EnFix ACL launched in April 2026 for ACL reconstruction. All EnFix implants leverage two proprietary, exclusively licensed technologies from TheraCell: Bone Textile, which produces long, strong demineralized cortical bone fibers that preserve collagen structure, nanotopography, and bone morphogenetic proteins, and FormLok, a patented shape-retention process that allows the implants to retain form when immersed in liquid during arthroscopic surgery.
The technology has a clinical legacy of more than 150,000 implants in spine applications prior to sports-medicine adaptation and is supported by nine issued US patents and one Australian patent. Tetrous generates revenue through hardware sales of single-use disposable EnFix implants to orthopedic and sports medicine surgeons and hospitals in the United States, Australia, and New Zealand, with distribution handled through a direct US commercial team, exclusive distributor Australian Biotechnologies (Australia, since 2023), exclusive distributor Alpha Medical (New Zealand, signed March 2025), and US manufacturing partner Origin Biologics. Adoption is driven primarily by surgeon KOL advocacy, peer-to-peer education at conferences such as AOSSM, AOFAS, ISAKOS, OSET, and Shoulder 360, and a growing body of clinical evidence including a reported 36% reduction in 12-month rotator cuff repair failure rates (8.3% to 5.3%) and 100% MRI-confirmed healing in a study of massive rotator cuff tears.
The company is led by co-founder, CEO and Chairman Bradley E. Patt, PhD (40+ years of medical-imaging and life-sciences entrepreneurial experience with three prior exits) and co-founder and CTO Andrew J. Carter, PhD (30+ years in orthobiologics with more than 50 US patents), alongside CCO John Bojanowski and VP of Sales Thurman Ballard (appointed March 2026). Tetrous closed a $6.5 million Series A financing in March 2025, with over 50% contributed by strategic manufacturing and distribution partners, and raised an additional approximately $1.74 million in April 2026. As of May 2026 the company had surpassed 3,500 implanted EnFix devices across more than 100 active surgeon users, with three-times year-over-year growth in surgeon adoption and implant volumes, and had been recognized as the sole recipient of the AOSSM ACE Award (2024) and the Shoulder 360 Most Exciting New Product award (2026).
Tetrous firmographics
Firmographics- Name
- Tetrous
- Legal name
- Tetrous, Inc.
- Website
- https://tetrous.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Tetrous, Inc. is a regenerative medicine company developing and commercializing the EnFix family of 100% demineralized bone fiber allograft implants for orthopedic and sports medicine surgeons performing bone-to-tendon repair procedures, including rotator cuff and ACL reconstruction, in the United States, Australia, and New Zealand.
- Ownership category
- akta.pro rank
Tetrous industry classification
Industry- Product category
- Orthopedic Sports Medicine Implants
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair) (HLAHAEAF)
- akta.pro secondary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
Keywords
Where Tetrous is headquartered
LocationHeadquarters
- HQ city
- Sherman Oaks
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Tetrous business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Medical Device / Implant Sales: Tetrous generates revenue through the sale of its EnFix family of demineralized bone fiber allograft implants (EnFix RC, EnFix TAC, EnFix ACL) to orthopedic surgeons and hospitals for use in sports medicine procedures including rotator cuff repair, biceps tenodesis, Achilles repair, and ACL reconstruction. Revenue is derived from direct commercial sales in the US and through distribution partners internationally. Implants are single-use disposable surgical products.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
Tetrous product offering
Product offeringCore offering
Tetrous develops, manufactures, and commercializes the EnFix family of 100% demineralized bone fiber (DBF) allograft implants for sports medicine applications, including rotator cuff repair, biceps tenodesis, Achilles repair, and ACL reconstruction. The company also supplies dedicated surgical instrument sets used to implant its EnFix products. Implants are sold to orthopedic surgeons, hospitals, and surgical centers in the United States, Australia, and New Zealand.
Product overview
Tetrous is a regenerative medicine company offering the EnFix family of 100% demineralized bone fiber (DBF) implants for bone-to-tendon healing in sports medicine. The core product line includes EnFix RC® (for use with suture anchors in rotator cuff repair), EnFix TAC-T® and EnFix TAC-O® (for use with all-suture anchors or anchor-independently), and EnFix ACL™ (for ACL reconstruction). All products utilize proprietary Bone Textile™ technology for long, strong fibers and FormLok™ technology for shape retention in wet surgical environments. The company also provides dedicated surgical instrument sets for each product line. These implants address Enthesis Failure Syndrome by promoting osteoinductivity and osteoconductivity at the bone-tendon interface, facilitating reformation of the native enthesis rather than scar tissue formation.
Differentiator
Problem solved
Functional benefit
Brands
- EnFix: Family of demineralized bone fiber (DBF) implants designed to enhance healing at the enthesis (bone-tendon interface). Includes EnFix RC (for use with suture anchors), EnFix TAC (for use independent of anchors or with all-suture anchors), and EnFix ACL (for ACL reconstruction).
- EnFix RC
- EnFix TAC
- EnFix ACL
- Bone Textile
- FormLok
Products and services
- EnFix RC A procedure-specific 100% demineralized bone fiber (DBF) allograft implant for rotator cuff repair, designed for use with suture anchors (4.5mm to 5.5mm and larger). Placed within bone at the bone-tendon interface (enthesis) to enhance healing. Targeted at orthopedic shoulder surgeons and sports medicine physicians.
- EnFix TAC A 100% demineralized bone fiber implant for rotator cuff repair available in two configurations: TAC-T (4mm x 10mm) and TAC-O (8.5mm diameter). Designed for use independent of suture anchors or with all-suture anchors, providing surgeons flexibility in rotator cuff repair. Targets orthopedic shoulder and sports medicine surgeons.
- EnFix ACL A 100% demineralized bone fiber (DBF) allograft implant for ACL reconstruction that promotes biological regeneration at the graft-bone interface. Utilizes FormLok shape retention technology and integrates with existing ACL reconstruction procedures. Targets orthopedic knee and sports medicine surgeons.
- EnFix Instrument Set Dedicated surgical instrument set for EnFix procedures, including instrument tray, cutting and non-cutting awls (4.5mm/5.5mm), introducer probe, pusher probe, guide wire (1.2 x 355mm), and dilator (5.5mm). Used by orthopedic surgeons to implant EnFix products.
Quantifiable outcome
- 36% reduction in rotator cuff repair failure rates at 12 months (from 8.3% without EnFix to 5.3% with EnFix)
- +6 more outcomes
Companies that use Tetrous
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles2 records
Tetrous technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Tetrous partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Alpha MedicalcoreAlpha Medical (New Zealand) signed an exclusive distribution agreement in March 2025 for distribution of Tetrous EnFix demineralized bone fiber implants in New Zealand for shoulder, elbow, hip, knee, and ankle procedures. Founded in 2023, Alpha Medical is an independent supplier of high-quality medical devices focused on orthopaedics and sports medicine surgery. CEO Brandon Hiini leads the experienced team.
- Origin BiologicscoreOrigin Biologics (Las Vegas, NV, USA) is Tetrous' US-based manufacturing partner with an FDA-approved facility. Origin Biologics was founded in 2017 by Simon Berry in partnership with the Nevada Donor Network. It is a strategic partner that invested over 50% of Tetrous' Series A funding round ($6.5M closed March 2025), demonstrating deep financial and operational commitment. Origin Biologics also manufactures EnFix products under strict quality standards (AATB, FDA registered).
- Australian BiotechnologiescoreAustralian Biotechnologies (Sydney, Australia) is Tetrous' exclusive distribution partner in Australia, established since the initial product launch in July 2023. It is a strategic partner that invested over 50% of Tetrous' Series A funding round. Founded by Simon Berry in 2002, it grew to be the largest manufacturer of allografts in Australia before being sold to LifeHealthcare (now EBOS Group). Simon Berry serves as CEO and Director of ABT Healthcare and as Director on Tetrous' Board.
- Millstone Medical OutsourcingminorMillstone Medical Outsourcing handles US distribution and logistics for Tetrous EnFix implants. Listed on Tetrous' resources page alongside FDA establishment registration and state tissue bank licenses (California, Connecticut, Delaware, Florida, Illinois, Louisiana, Maryland, New York, Oregon).
- TheraCell, Inc. (ISTO Biologics)coreTheraCell, Inc. (an ISTO Biologics Company) is the licensor of the demineralized bone fiber technology used in Tetrous' EnFix products, exclusively licensed for sports medicine applications. Tetrous was spun out of TheraCell in 2019 before TheraCell was sold to ISTO Biologics in 2022. TheraCell also owns the Bone Textile and FormLok trademarks. The core DBF technology has been used in over 150,000 implants in spine applications prior to sports medicine adaptation.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Tetrous competitors and assessment
Company assessmentBroad incumbents
- Arthrex: Arthrex is the dominant privately held sports medicine and orthopedic soft-tissue repair company, offering anchors, grafts, patches, and biologic solutions that compete with Tetrous' EnFix line in rotator cuff and ACL reconstruction. Comparable as a sports medicine implant peer with deep surgeon relationships.
- Smith & Nephew: Smith & Nephew is a global medical device incumbent with a large sports medicine franchise (including REGENETEN bioinductive implant and Healicoil anchors) that competes directly with Tetrous in rotator cuff repair and biologics. Comparable as a broad sports medicine and orthobiologics peer.
- Stryker: Stryker (including its Wright Medical / Tornier shoulder portfolio) sells sports medicine implants, suture anchors, and orthobiologics in rotator cuff and soft-tissue repair, competing with Tetrous' EnFix offerings across multiple entheses. Comparable as a large incumbent orthopedics peer.
- Johnson & Johnson (DePuy Synthes Mitek Sports Medicine): J&J's Mitek Sports Medicine division is a leading global sports medicine franchise offering suture anchors, grafts, and biologic augmentation products that compete with Tetrous in rotator cuff and ACL repair. Comparable as a broad incumbent peer in sports medicine soft-tissue repair.
- Conmed: Conmed is a sports medicine and orthopedic device company offering suture anchors, tissue repair devices, and biologic solutions in rotator cuff and ACL reconstruction. Comparable as a broad sports medicine incumbent competing for surgeon share against Tetrous.
Direct peers
- MTF Biologics: MTF Biologics is the largest US tissue bank providing allograft and demineralized bone matrix (DBM) products used in sports medicine and orthopedic procedures. Comparable as the closest direct peer to Tetrous in the demineralized bone fiber / allograft orthobiologics space.
- LifeNet Health: LifeNet Health is a leading allograft tissue bank offering demineralized bone matrices and sports medicine grafts, competing in the same orthobiologics category as Tetrous' EnFix DBF implants. Comparable as a direct peer in allograft-based sports medicine biologics.
- Bioventus: Bioventus is an orthobiologics company offering bone healing and joint preservation products (including sports medicine-relevant offerings), competing in the biologic augmentation space where Tetrous operates. Comparable as a focused orthobiologics peer.
- ISTO Biologics (TheraCell parent): ISTO Biologics acquired TheraCell in 2022 and holds the underlying DBF technology licensed to Tetrous; it markets orthobiologics including bone graft substitutes in spine and sports. Comparable as the licensor and a direct competitor in DBF-based sports medicine orthobiologics.
Emerging players
- Anika Therapeutics: Anika Therapeutics is a regenerative medicine and orthobiologics company developing hyaluronic-acid-based and other implant products for orthopedic applications. Comparable as an emerging player in orthopedic regenerative medicine with overlapping sports medicine ambitions; CTO Andrew Carter's prior affiliation adds a leadership-level connection.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Tetrous social profiles
Digital presenceTetrous compliance and trust
Trust signalCompliance3 records
Tetrous financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tetrous leadership team
Management profileNumber of profiles
Profiles1 record
Tetrous funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tetrous M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tetrous
What does Tetrous do?
Tetrous develops, manufactures, and commercializes the EnFix family of 100% demineralized bone fiber (DBF) allograft implants for sports medicine applications, including rotator cuff repair, biceps tenodesis, Achilles repair, and ACL reconstruction. The company also supplies dedicated surgical instrument sets used to implant its EnFix products. Implants are sold to orthopedic surgeons, hospitals, and surgical centers in the United States, Australia, and New Zealand.
Is Tetrous a public or private company?
Tetrous is a private company. It is classified as venture growth investor backed and is currently operating.
When was Tetrous founded?
Tetrous was founded in 2019. It employs 1 to 10 people.
Where is Tetrous based?
Tetrous is headquartered in Sherman Oaks, United States, in the North America region.
How does Tetrous make money?
One revenue line is on record: medical Device / Implant Sales.
Who are Tetrous's main competitors?
Broad incumbents on record are Arthrex, Smith & Nephew, Stryker, Johnson & Johnson (DePuy Synthes Mitek Sports Medicine) and Conmed. Direct peers are MTF Biologics, LifeNet Health, Bioventus and ISTO Biologics (TheraCell parent). Anika Therapeutics is listed as an emerging player.
Does Tetrous have an API?
No public API is recorded for Tetrous.
What industry is Tetrous in?
Tetrous's product category is Orthopedic Sports Medicine Implants. Its primary akta.pro industry code is HLAHAEAF, Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair), with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 339113 and its SIC code is 3842.